Dompé U.S. Agrees to Pay $32M to Resolve False Claims Act Liability Relating to Self-Disclosure of Patient Kickbacks
Dompé U.S. Inc. (Dompé), based in California, has agreed to pay $32 million to resolve allegations that, between 2018 and 2021, it paid Medicare beneficiary co-pays through two patient assistance foundations to induce the purchase of its drug, Oxervate, in violation of the Anti-Kickback Statute and the False Claims Act.
Se muestra el contenido original; la traduccion localizada aun no esta disponible.
Qué ocurrió
Dompé U.S. Inc. (Dompé), based in California, has agreed to pay $32 million to resolve allegations that, between 2018 and 2021, it paid Medicare beneficiary co-pays through two patient assistance foundations to induce the purchase of its drug, Oxervate, in violation of the Anti-Kickback Statute and the False Claims Act.
Por que importa
The development may change operating conditions or market expectations around Regulation. Further confirmation and measurable outcomes matter.
Entidades afectadas
Ver evidencia
1 articulos · 1 informe original · 1 independientes
- U.S. Department of JusticeFuente primaria · Respalda · EN · 100%Dompé U.S. Agrees to Pay $32M to Resolve False Claims Act Liability Relating to Self-Disclosure of Patient Kickbacks ↗
Afirmaciones
- Dompé U.S. Agrees to Pay $32M to Resolve False Claims Act Liability Relating to Self-Disclosure of Patient Kickbacks Observado
Conflictos
No se detectaron conflictos importantes en la evidencia disponible.
Cronología
- Primera publicación
Movimiento del mercado posterior al evento
La reacción del mercado aún no está disponible para este activo y periodo.